FilingReader Intelligence

SMS Pharma revenue jumps 19% to ₹196 crore

August 10, 2025 at 04:19 PM UTCBy FilingReader AI

SMS Pharmaceuticals reported revenue growth of 19% year-on-year to ₹196.05 crore for Q1 FY26, driven by higher volumes and strong demand for key Active Pharmaceutical Ingredients.

EBITDA rose 17% to ₹39.37 crore with margins stable at 20%. Profit after tax surged 24% to ₹20.50 crore.

The company has commissioned its backward integration project and is pursuing a ₹250 crore capacity expansion program funded by internal accruals and debt.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

BSE:SMSPHARMABombay Stock Exchange

News Alerts

Get instant email alerts when SMS Pharmaceuticals publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →